FDA
-
-
-
-
-
-
-
GRAIL Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Superpower partners with GRAIL to offer multi-cancer blood test
-
-
-
-
-
-
-
GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Canaccord Genuity Reiterates Buy Rating on GRAIL, Inc. (GRAL)
-
-
-
-
-
-
-
Samsung units invest $110 million in GRAIL for Asia cancer test push
-
-
-
-
-
-
-
GRAIL, Inc. (GRAL) PT Raised to $43 at Canaccord Genuity, 'We believe the shares do not reflect the company's growth potential'
-
-
-
-
-
-
-
GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System
-
325,553 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

